Merck/Endocyte Mulling Vintafolide’s Future After Failure In Ovarian Cancer

Endocyte is potentially propelled back to a Phase I company after its nearest commercial prospect flops and its collaboration with Merck is expected to disintegrate now that the drug missed PFS in ovarian cancer.

Endocyte Inc. and partner Merck & Co. Inc. have another shot with vintafolide with a lung cancer trial due to report on overall survival in the fall – but the compound took a major hit when a data safety monitoring board stopped a Phase III ovarian cancer trial due to lack of efficacy.

The drug, a conjugate of folic acid that targets folate receptors on the surface of cancer cells and is linked...

More from United States

More from North America